title: CD83(+) dendritic cells and Foxp3(+) regulatory T cells in primary lesions and regional lymph nodes are inversely correlated with prognosis of gastric cancer.
abstract: BACKGROUND
  Dendritic cells (DCs) are potent antigen-presenting cells that are central to the regulation, maturation, and maintenance of the cellular immune response against cancer. In contrast, CD4(+)CD25(+) regulatory T cells (Tregs) play a central role in self-tolerance and suppress antitumor immunity. In this study, we investigated the clinical significance of mature CD83(+) DCs and Foxp3(+) Tregs in the primary tumor and regional lymph nodes from the viewpoint of the two opposing players in the immune responses.
  
  
  METHODS
  We investigated, immunohistochemically, the density of CD83(+) DCs and Foxp3(+) Tregs in primary lesions of gastric cancer (n = 123), as well as in regional lymph nodes with (n = 40) or without metastasis (n = 40).
  
  
  RESULTS
  Decreased density of CD83(+) DCs and increased density of Foxp3(+) Tregs were observed in the primary tumor and metastatic lymph nodes. Density was significantly correlated with certain clinicopathological features. Poor prognosis was observed in patients with a low density of CD83(+) DCs and a high density of Foxp3(+) Tregs in primary lesions. For patients with metastatic lymph nodes, the density of CD83(+) DCs in negative lymph nodes was found to be an independent prognostic factor by multivariate analysis.
  
  
  CONCLUSIONS
  The density of CD83(+) DCs and Foxp3(+) Tregs was inversely correlated with tumor progression and reflected the prognosis of gastric cancer.
authors.affiliation: Department of Surgery I, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan.
authors.forename: Seigo
authors.initials: S
authors.lastname: Kashimura
authors.forename: Zenichiro
authors.initials: Z
authors.lastname: Saze
authors.forename: Masanori
authors.initials: M
authors.lastname: Terashima
authors.forename: Nobutoshi
authors.initials: N
authors.lastname: Soeta
authors.forename: Satoshi
authors.initials: S
authors.lastname: Ohtani
authors.forename: Fumihiko
authors.initials: F
authors.lastname: Osuka
authors.forename: Michihiko
authors.initials: M
authors.lastname: Kogure
authors.forename: Mitsukazu
authors.initials: M
authors.lastname: Gotoh
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000938:Antigen-Presenting Cells / Q000276:immunology*; D015703:Antigens, CD / Q000032:analysis*; D003713:Dendritic Cells / Q000276:immunology*; D005260:Female; D051858:Forkhead Transcription Factors / Q000032:analysis*; D006801:Humans; D007108:Immune Tolerance; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008198:Lymph Nodes / Q000276:immunology* / Q000473:pathology; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D000071176:Signaling Lymphocytic Activation Molecule Family; D013274:Stomach Neoplasms / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D015996:Survival Rate; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*; D055815:Young Adult
chemical_list: D015703:Antigens, CD; C498970:CD84 protein, human; C418974:FOXP3 protein, human; D051858:Forkhead Transcription Factors; D000071176:Signaling Lymphocytic Activation Molecule Family
references.citation: Clin Cancer Res. 2007 Feb 1;13(3):902-11
references.pmid: 17289884
references.citation: Clin Cancer Res. 2006 Sep 15;12(18):5423-34
references.pmid: 17000676
references.citation: J Immunol. 1992 Jul 15;149(2):735-42
references.pmid: 1378080
references.citation: Immunol Rev. 2006 Aug;212:8-27
references.pmid: 16903903
references.citation: J Immunol. 2017 Feb 1;198(3):986-992
references.pmid: 28115587
references.citation: Clin Cancer Res. 2007 Apr 1;13(7):2075-81
references.pmid: 17404089
references.citation: Immunity. 2008 Mar;28(3):402-13
references.pmid: 18328743
references.citation: Int J Cancer. 2003 Mar 10;104(1):92-7
references.pmid: 12532424
references.citation: Cancer. 1990 May 15;65(10):2261-5
references.pmid: 2346911
references.citation: J Immunol. 1995 Apr 15;154(8):3821-35
references.pmid: 7706722
references.citation: Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4345-54
references.pmid: 17671115
references.citation: Oncol Rep. 2005 Aug;14(2):353-6
references.pmid: 16012714
references.citation: Int Immunol. 2004 Dec;16(12):1769-80
references.pmid: 15520045
references.citation: Immunity. 2007 Jul;27(1):145-59
references.pmid: 17613255
references.citation: J Immunol. 2008 Apr 1;180(7):4679-86
references.pmid: 18354191
references.citation: Cancer Immunol Immunother. 2004 Nov;53(11):1018-26
references.pmid: 15185013
references.citation: J Exp Med. 1999 Nov 15;190(10):1417-26
references.pmid: 10562317
references.citation: Science. 2003 Feb 14;299(5609):1057-61
references.pmid: 12522256
references.citation: Int J Cancer. 1996 Sep 27;68(1):1-7
references.pmid: 8895531
references.citation: J Immunol. 2007 Apr 1;178(7):4089-96
references.pmid: 17371963
references.citation: Blood. 2006 Aug 1;108(3):804-11
references.pmid: 16861339
references.citation: Cancer Immunol Immunother. 2004 Nov;53(11):978-86
references.pmid: 15197496
references.citation: Cancer Res. 2001 Jun 15;61(12):4766-72
references.pmid: 11406550
references.citation: Hum Pathol. 2004 Nov;35(11):1392-6
references.pmid: 15668897
references.citation: Immunology. 2006 Mar;117(3):289-300
references.pmid: 16476048
references.citation: N Engl J Med. 1992 Jul 2;327(1):14-8
references.pmid: 1317941
references.citation: Clin Cancer Res. 2005 Dec 1;11(23):8326-31
references.pmid: 16322292
references.citation: Br J Cancer. 2008 Jan 15;98(1):148-53
references.pmid: 18087278
references.citation: Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2588-92
references.pmid: 8637918
references.citation: Clin Cancer Res. 2006 Jan 15;12(2):465-72
references.pmid: 16428488
references.citation: Mol Ther. 2005 Nov;12(5):922-32
references.pmid: 16257383
references.citation: J Surg Oncol. 2007 Feb 1;95(2):123-8
references.pmid: 17262742
references.citation: Cancer. 1990 Nov 1;66(9):2012-6
references.pmid: 2224800
references.citation: Cancer Res. 1998 Aug 15;58(16):3491-4
references.pmid: 9721846
references.citation: J Surg Res. 2005 Mar;124(1):151-7
references.pmid: 15734494
references.citation: Annu Rev Immunol. 2000;18:767-811
references.pmid: 10837075
references.citation: J Immunol. 1995 Aug 1;155(3):1151-64
references.pmid: 7636184
references.citation: Oncol Rep. 2005 Aug;14(2):369-75
references.pmid: 16012717
references.citation: J Immunother. 2001 Mar-Apr;24(2):130-7
references.pmid: 11265770
references.citation: J Exp Med. 2001 Jun 4;193(11):1285-94
references.pmid: 11390435
references.citation: Immunity. 2005 Mar;22(3):329-41
references.pmid: 15780990
references.citation: Blood. 2001 Nov 1;98(9):2736-44
references.pmid: 11675346
references.citation: Gastric Cancer. 1998 Dec;1(1):10-24
references.pmid: 11957040
references.citation: Ann Surg Oncol. 2006 Sep;13(9):1252-8
references.pmid: 16952047